Use of Anti-her3 antibody-drug conjugate in treating tumors and method for treating tumors using Anti-her3 antibody-drug conjugate
By using anti-HER3 antibody drug conjugates to bind tyrosine kinase inhibitors, the problem of difficulty in effective treatment of advanced HER3 mutations and/or metastatic NSCLC in the prior art is solved, and significant anti-tumor effects and safety are achieved.
WO2025061145A1 Publication Date: 2025-03-27JIANGSU HENGRUI MEDICINE CO LTD
8 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2024/120021
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-29
- Filing Date
- 2024-09-20
- Publication Date
- 2025-03-27
AI Technical Summary
Technical Problem
It is difficult to develop safe and effective clinical therapeutic strategies to target HER3 targets, especially in the treatment of advanced and/or metastatic non-small cell lung cancer (NSCLC) of HER3 mutations.
Method used
The treatment method of anti-HER3 antibody drug conjugates (ADCs) combined with tyrosine kinase inhibitors is used to achieve anti-tumor effects by targeting HER3 receptors and inhibiting related signaling pathways.
Benefits of technology
This approach significantly improves the therapeutic effect of HER3-mutated tumors, especially in patients who fail to treat EGFR-TKI, showing encouraging anti-tumor activity and tolerable safety.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to a use of an anti-HER3 antibody-drug conjugate in treating tumors and a method for treating tumors using the anti-HER3 antibody-drug conjugate. Specifically, the present disclosure relates to the use of an anti-HER3 antibody-drug conjugate in the preparation of a drug for treating EGFR-mutant tumors. The anti-HER3 antibody-drug conjugate has a structure as shown in formula I.
Need to check novelty before this filing date? Find Prior Art